Answers are grounded in this paper and cite their sources.
Solitary fibrous tumors (SFT) are a rare class of mesenchymal tumors constituting about 2% of all soft tissue tumors (1, 2,3). SFTs show a tendency to arise from serosal membranes of body cavities with thoracic sites being the commonest. Extra-thoracic SFTs arise in deep soft tissues of the abdominal cavity, head and neck, orbit, and proximal extremities. They represent less than 6% of retroperitoneal sarcomas and have an annual incidence of 1 case per one million person per year (1). The World Health Organization classification of 2020 described SFTs as intermediate potential low metastatic risk mesenchymal tumors (4,5). Due to their rarity and lack of high-level evidence, there is no consensus regarding management. Margin negative surgical excision remains the treatment of choice but the complexity and spectrum varies due to varied location and presentation. The previously used terms Benign and Malignant SFTs are currently avoided, as even the benign SFTs do rarely have local and metastatic recurrences with incidence up to 45% (6,7). Some series report relapse rates as high as 10% even after 10 years (7,8). Several risk stratification models had been proposed to predict recurrence and survival for SFTs, with the modified Demicco model being the most widely reported (8,9). This study reports surgical outcomes and relapse patterns of extra thoracic SFTs. We examine the role of adjuvant radiation, tailoring of follow-up based on risk stratification and utility of salvage treatment in recurrent cases.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: